

Thank you Professor Chizzolini for your introduction and the opportunity to talk today. As you now know I am a patient with Eosinophilic Fasciitis whose disease is in remission. What I want to share with you is drawn from my own experience and what other patients have posted in online forums. I will call this forum data.

## Main findings

- 1. It is taking too long to diagnose this disease
- 2. Current practice is high dose prednisone from the start with methotrexate being the ISD of first choice if needed
- 3. There are no double-blind studies to validate any treatment
- 4. There are more young patients than the studies make you believe
- 5. Patients who do more for themselves fare better
- 6. Patients suspect stress as the main trigger
- 7. A genetic predisposition seems likely but there is not enough research
- 8. Patient data can be extracted from unstructured text

2017-06-22 15:02

Martin O. G. FitzGerald © 2017

All these findings will be addressed by the slides.

(1) The forum data shows it is taking to long to diagnose this disease

(2) Recent studies show that this treatment is effective and the forum data generally support it [ISD=immuno-suppressant drug]

(3) There are too few patients for double-blind studies

(4) The forum data contains more young patients than the studies

(5) The forum statistics show that proactive patients do better


(6) The clinical studies propose unusual physical exertion as the most common trigger,

but patients put more blame on stress


(7) There is some evidence for EF occurring in families

(8) What this project tries to demonstrate is how data mining of what patients **write**, can add to what doctors **know** 

2



I will start with some pictures just to give an idea of this disease. Then see what patients find online. Refer to some studies. Show where patients post their stories. Show how we can convert that to data and run queries. See some cases of this disease in families. See how the W-H-O classifies this disease and finish up with some thoughts and suggestions.



These pictures are from one of the studies. My legs looked like this. The tight shiny edematous skin is typical of this disease. The MRI was a turning point in my diagnosis. My generalist said he would not have been able to interpret my MRI pictures, only a specialist could. Perhaps there is software that can. The biopsy samples apparently show fascia inflammation and infiltration of eosinophils. To me they look just like modern art.




This shows how to check the Modified Rodnan Skin Score. I had this done each month to measure my progress.




I had grooves like this on both sides of my arms. When I showed an intern, unsurprisingly he had no idea what they were. I imagine these grooves are not a major topic at medical school.



My arms had the peau d'orange look, like this leg. But not like that arm which is at a worse stage of the disease. That lumpy appearance seems to affect women more than men. One of my physiotherapists thought it might be an adipose effect.




I had swollen hands at first which turned into the famous "claw hands" shown here. I couldn't open or close them properly. It is a very common symptom of this disease and is often described as carpal tunnel syndrome but I am not sure if it's really the same thing when the underlying cause is different.



I was alarmed by my symptoms and worried about getting worse. Like other patients, I looked for answers online.

	Professional health sites for EF patients	
	http://www.merckmanuals.com//eosinophilic-fasciitis/	
	MERCK MANUAL Professional Version	
	https://rarediseases.org/rare-diseases/eosinophilic-fasciitis/	
	NORD Kational Organization for Rare Disorders	
	http://apfed.org/about-ead/eosinophilic-fasciitis/	
	American Partnership for Eosinophilic Disorders	
	http://www.mdguidelines.com/eosinophilic-fasciitis	
	http://www.sclero.org/scleroderma/autoimmune/skin-diseases/eosinophilic-fasciitis/a-to-z.html	
	SCLERO.ORG	
	https://rarediseases.info.nih.gov/diseases/6351/index	
	GARD Genetic and Rare Diseases Information Center	
2017-06-22 15:02	Martin O. G. FitzGerald © 2017	10

Although it's still common advice to avoid looking up your condition online, in today's digital world this is unavoidable. So what can patients find? Here are some patient-friendly sites about this disease which are informative and have no paywall.




I learned about these from another patient who recommended them.

r	The	se clinical studies were used as guides
1979	20	University of Pittsburgh School of Medicine, Pennsylvania, USA A Pathologic Study of Twenty Cases
1988	52	Mayo Clinic, Rochester, Minnesota, USA Clinical Spectrum and Therapeutic Response in 52 Cases
2006	11	Stadtspital Triemli Zürich, Universitätsspital Basel, Switzerland 30 Years after – What Do We Really Know?
2011	34	Hôpital Pitié-Salpêtrière, Paris, France new insights into the therapeutic management
2014	16	Mayo Clinic, Jacksonville, Florida, USA clinical characteristics and response to methotrexate
2016	63	Brigham and Women's Hospital, Boston, Massachusetts, USA An Analysis of 63 Patients From 3 Tertiary Care Centers


These studies are interesting for their fairly large patient cohorts. The 1988 Mayo Clinic study seemed to set a standard for the others. The 2016 Brigham and Women's study found there was a strong case for the combination of corticosteroids and methotrexate. It also found that patients diagnosed within 6 months fared slightly better. I looked for this correlation among the forum patients but it wasn't obvious. That seems counter-intuitive but I have to respect the data. So far there have been no double-blind studies to validate treatments. There are simply not enough of us. Perhaps there have been double-blind studies on other eosinophilic disorders that might be informative.

And the	re are forums where EF patier post their stories	nts
	forums : 5 patients : 242 threads : 1300 postings : 16,000 words : 975,000	
2017-06-22 15:02	Martin O. G. FitzGerald © 2017	13


This was the input to my project. I selected 242 patients for inclusion in the database. You can see that they posted nearly a million words, all of which had to be read and converted to data.



These are the places where patients posted their stories. There is moral support, no criticism, no time constraints and the comfort of being at home. Some patients are health professionals who give good advice. Most of the patients who post in these forums are from North America and English speaking countries, only a few are from Europe. The **global** occurrence of this disease is still unknown.



I used my IT knowledge (I am a software developer) to format and load the patient data into a relational database. Once that was done it was easy to write queries that looked for interesting things.




I could not automatically convert what patients say into data. I had to read it all. But I made this tool that extracts the "interesting" words for each patient. I did not make a "white list" of these words, but did the opposite. I made an exclusion list of the "uninteresting" words so that whatever words are left are selected and counted. This ensures that new words are interesting until I decide they are not. A lookup table handles misspellings.

| 07 7<br>13 9 | 2 )   |   
   
   
  |  |   | eum   | snia  | arm   | elbs  | wrst  | carp  | hnds  | hips  | nts leg  | s thig   
   | calv   | kne  | shns a   | nks fee  
   
   | et sols   | trnk   | back   
   
  | abd c  
   
  | hst re   | sp necl  | k thrt   
   | face   | jaw r  | nph  | rmp p  | ain n  | nph it   | ch fat   | ig stg   | h wgh  | hair   
   | fevr   | uwk  | CT  | MRI  bi   | iop   | eos s   |
|--------------|---
--
--
--
--|--|---|---|---|---|---|---|---|---|---|--|--
--|--|--
--
--
--|---|--
--
--
---
--
---
--|--|--|--|--|--|--|--|--|--
--|--|--|--|--|---|---|---|---|
| 13 9         |   | Y   
   
   
  |  | Y   | Y   |   | Y   |   | Y   | Y   | Y   |   | ΥY   |  
   |  |  | Y  | ΥY   
   
   | Y   |  | Y  
   
  |  
   
  |  |  | | | | | | | |
   |  |  |  | Y  | Y  | Y  | Y  | Y  |  |  
   |  |  | Y   |   | Y   | Y   |
|              | 3 Y   | Y   
   
   
  | Y  | Y   | Y   |   | Y   |   |   |   |   |   | Y  | Y  
   |  |  |  | ΥY   
   
   |   | Y  |  
   
  |  
   
  | 1  | 1  | | | | | | | |
   |  |  |  |  | Y  | Y  | ΥÌ   |  | Y  |  
   | Y  |  |   |   | Y   | Y   |
| 14 8         | 3 Y   | Y   
   
   
  |  |   | Y   | Y   | Y   | Y   | v         v   |   |   |   |  |  
   |  |  |  |  
   
   |   |  |  
   
  |  
   
  |  | Y  | Y  
   |  |  |  |  |  |  |  |  |  |  
   |  |  |   |   |   |   |
| 12 7         | 4 Y   | Y   
   
   
  |  | Y   |   | Y   | Y   |   | Y   |   |   |   |  |  
   |  |  |  |  
   
   | Y   |  | Y  
   
  | Y  
   
  | Y  | Y  | Y  
   | Y  |  |  |  |  |  |  |  |  |  
   |  |  |   |   |   |   |
| 14 12        | 3 Y   | Y   
   
   
  |  |   | Y   |   | Y   |   |   | Y   |   |   | Y  | Y  
   |  | Y  |  | Y  
   
   |   |  |  
   
  | Y  
   
  |  |  | | | | | | | |
   |  |  |  |  |  |  | )  |  |  |  
   |  | Y  |   |   | Y   | Y   |
| 05           | 5   |   
   
   
  |  |   |   |   |   |   |   |   |   |   |  |  
   |  |  |  |  
   
   |   |  |  
   
  |  
   
  |  |  | | | | | | | |
   |  |  |  |  |  |  |  |  |  |  
   |  |  |   |   |   |   |
| 13 10        | 4 Y   | Y   
   
   
  | Y  | Y   | Y   |   | Y   | Y   | Y   | Y   | Y   |   | ΥY   | Y  
   |  | Y  |  | ΥY   
   
   |   |  |  
   
  |  
   
  |  |  |  
   |  |  | Y  |  | Y  | Y  | ΥÌ   | Y  | Y  | Y  
   | Y  | Y  |   | Y   |   |   |
| 14 20        | 4 Y   | Y   
   
   
  | Y  | Y   | Y   |   | Y   |   | Y   | Y   | Y   |   | Y  | Y  
   | Y  |  |  | ΥY   
   
   | Y   |  | Y  
   
  |  
   
  |  |  |  
   | Y  |  |  |  | Y  | Y  | ΥÌ   | Y  |  | Y  
   | Y  | Y  |   | Y   | Y   | Y   |
| 97 6         | 20 Y  | Y   
   
   
  | Y  | Y   | Y   |   | Y   | Y   | Υ   | Y   | Y   |   | ΥY   |  
   |  | Y  |  | ΥY   
   
   |   | Y  | Y  
   
  | Y  
   
  | ΥÌ   | Y Y  | | | | | | | |
   |  |  | Y  |  | Y  |  | N  |  | Y  |  
   |  | Y  |   |   | Y   | Y   |
| 13 6         | 4 Y   | Y   
   
   
  |  |   | Y   |   | Y   |   | Y   |   | Y   |   | Y  | Y  
   |  | Y  |  | Y  
   
   |   |  |  
   
  |  
   
  |  |  | | | | | | | |
   |  |  |  |  | Y  | Y  | 1  |  |  |  
   |  |  | Y   | Y   | Y   | Y   |
| 14 7         | 2 Y   | Y   
   
   
  | Y  |   | Y   |   | Y   |   |   |   |   |   | Y  | Y  
   |  | Y  |  |  
   
   |   |  | Y  
   
  | Y  
   
  |  | Y  | Y  
   |  |  |  | Y  | Y  | Y  | ΥÌ   | Y  |  |  
   | Y  |  |   |   | Y   | Y   |
| 15 13        | 3 Y   | Y   
   
   
  | Y  | Y   | Y   |   | Y   |   |   | Y   | Y   |   | ΥY   |  
   | Y  | Y  | Y  | ΥY   
   
   |   |  | Y  
   
  |  
   
  |  |  |  
   |  |  | Y  |  | Y  | Y  | ΥÌ   | Y  | Y  | Y  
   |  |  | Y   | Y   | Y   | Y   |
| 14 12        |   | Y   
   
   
  | Y  | Y   | Y   |   | Y   |   | Y   |   | Y   |   | Y  | Y  
   | Y  |  |  | Y  
   
   | Y   | Y  |  
   
  | Y  
   
  | 1  | Y Y  | | | | | | | |
   |  |  |  | Y  |  |  | Y N  | Y  | Y  |  
   | Y  | Y  | Y   | Y   | Y   | Y   |
| 14 10        | 2   |   
   
   
  | Y  |   | Y   | Y   | Y   | -   | Y   |   | Y   |   | Y  |  
   | Y  |  |  | Y  
   
   |   |  |  
   
  |  
   
  | 1  | Y Y  | | | | | | | |
   |  | -  |  |  | Y  | Y  | 1  | Y  | Y  |  
   |  | Y  | -   |   | Y   |   |
| 14 8         | 3   | Y   
   
   
  | Y  | Y   | Y   |   | Y   | -   |   | Y   | _   | Y   |  |  
   |  | Y  | _  | _  
   
   |   |  |  
   
  | Y  
   
  | _  | _  | | | | | | | |
   |  | -  |  |  |  | Y  | _  | _  | Y  |  
   |  |  |   |   | Y   | Y   |
| 00           | 15  |   
   
   
  | 1  |   |   |   |   |   |   |   |   |   | Y  |  
   |  |  |  | Y  
   
   |   |  |  
   
  |  
   
  |  |  | | | | | | | |
   |  |  |  |  |  |  | 1  | Y  |  |  
   |  | Y  |   |   | -   |   |
| 10 10        | 2)  | Y   
   
   
  | Y  | Y   | Y   |   | Y   |   | Y   | Y   | Y   |   | YY   |  
   | Y  | Y  | Y  | ΥY   
   
   |   |  | Y  
   
  |  
   
  |  |  | | | | | | | |
   |  |  |  | Y  | Y  | Y  | 1  | Y  | Y  |  
   |  |  |   |   | Y   | Y   |
| 13 5         |   | Y   
   
   
  |  |   | Y   |   | Y   |   |   | Y   | Y   |   | Y  |  
   | Y  |  |  | Y  
   
   | Y   |  |  
   
  | Y  
   
  | Y  | Y  | Y  
   | Y  | Y  |  |  | Y  |  | γĹ   |  |  |  
   |  | Y  |   |   | Y   |   |
| 13 4         | 3   |   
   
   
  |  |   | Y   |   | Y   |   |   |   | Y   |   | Y  | Y  
   | 1  |  |  | Y  
   
   | Y   |  | Y  
   
  |  
   
  |  |  | | | | | | | |
   |  |  | Y  |  |  |  |  |  |  |  
   |  | Y  |   | Y   | Y   |   |
| 13 24        | 4 Y   | Y   
   
   
  |  |   | Y   | Y   | Y   |   | Y   | Y   | Y   |   | YY   |  
   | 1  | Y  |  | Y  
   
   | Y   |  | Y  
   
  |  
   
  | -  | r  | | | | | | | |
   |  |  |  | Y  | Y  | Y  | 1  | Y  |  |  
   | Y  | Y  |   | Y   | γŤ  | Y   |
| 13 9         | 4   | ,   
   
   
  |  |   | Y   |   | Y   | Y   | Y   | Y   | Y   |   | YY   | Y  
   | Y  | Y  |  | ΥY   
   
   |   |  |  
   
  | Y  
   
  |  | Y  | | | | | | | |
   |  | Y  |  |  | Y  | Y  | 1  |  |  |  
   |  |  | Y   | Y   | Y   | Y   |
| 13 2         | 3   |   
   
   
  | Y  | Y   | Y   |   | Y   |   |   |   | Y   |   | Y  |  
   |  |  |  |  
   
   |   |  |  
   
  |  
   
  |  |  | | | | | | | |
   |  |  |  |  |  |  |  |  | Y  |  
   |  |  |   | Y   | Y   |   |
| 13           | 2   |   
   
   
  |  |   | Y   |   |   |   |   |   | Y   |   |  |  
   |  |  |  |  
   
   |   |  |  
   
  |  
   
  |  |  | | | | | | | |
   |  |  |  |  | Y  |  |  |  |  |  
   |  |  |   |   |   |   |
| 13           | 3 1   |   
   
   
  |  |   |   |   | Y   |   | Y   |   |   |   | Y  |  
   |  |  |  |  
   
   |   |  |  
   
  |  
   
  |  |  | | | | | | | |
   |  |  |  |  |  | Y  |  |  |  |  
   |  |  |   |   | Y   |   |
|              | N   | Y   
   
   
  |  | Y   |   |   | Y   |   |   |   | Y   |   | Y  | Y  
   |  |  |  | Y  
   
   |   |  |  
   
  |  
   
  |  |  | | | | | | | |
   |  |  |  |  | Y  | Y  |  | +  | Y  |  
   |  |  |   |   | Y   |   |
| 13 5         | 3   |   
   
   
  |  |   |   |   |   |   |   |   | Y   |   | Y  |  
   |  |  |  | Y  
   
   |   |  |  
   
  |  
   
  |  |  | | | | | | | |
   | Y  | Y  |  |  |  | Y  |  |  |  |  
   |  | Y  |   |   | _   |   |
| 05           | 3   | Y   
   
   
  |  |   |   |   | Y   |   |   |   | Y   |   | Y  |  
   | 1  |  |  | Y  
   
   |   | Y  |  
   
  |  
   
  | Y  |  | | | | | | | |
   |  |  | Y  |  |  |  | 1  | Y  |  |  
   |  |  |   |   |   |   |
| 15 5         | 2   |   
   
   
  | Y  |   |   |   | Y   |   |   |   |   |   | Y  |  
   |  |  |  |  
   
   |   | Y  | Y  
   
  |  
   
  |  |  | | | | | | | |
   | Y  |  | Y  |  | Y  |  |  |  | Y  |  
   |  |  |   |   |   |   |
| 15 3         | 2   |   
   
   
  |  |   | Y   |   | Y   |   |   |   | Y   |   | Y  |  
   |  |  |  |  
   
   |   |  |  
   
  |  
   
  |  |  | Y  
   |  |  |  |  | Y  |  | 1  |  |  |  
   | Y  |  | Y   | Y   | Y   | Y   |
| 97           |   | Y   
   
   
  | 1  |   | Y   |   |   | Y   | Y   | Y   | Y   | Y   | Y  | Y  
   | 1  |  |  | ΥY   
   
   |   |  |  
   
  |  
   
  | 1  |  | 1  
   |  |  | Y  |  |  | Y  | Y I Y  |  |  |  
   |  |  |   |   | Y   | Y   |
| 15           |   |   
   
   
  | 1  |   |   |   |   |   |   |   |   |   |  |  
   | 1  |  |  |  
   
   |   |  |  
   
  |  
   
  |  |  | | | | | | | |
   |  |  |  |  |  |  |  |  |  |  
   |  |  |   |   | 1   |   |
| 13 8         | 3 1   | Y   
   
   
  |  |   |   |   | Y   |   |   |   | Y   |   | Y  |  
   |  |  |  |  
   
   |   | Y  |  
   
  |  
   
  |  |  | Y  
   |  |  |  | Y  | Y  |  | 1  |  | Y  |  
   | Y  | Y  |   |   | Y   |   |
| 10           | 6   | Y   
   
   
  |  |   |   |   | Y   | Y   |   |   |   |   |  |  
   |  |  |  |  
   
   |   |  |  
   
  |  
   
  |  |  | | | | | | | |
   |  |  |  |  |  |  | 1  |  |  |  
   |  |  |   |   | Y   |   |
|              |   | Y   
   
   
  |  |   | Y   |   | Y   | Y   | Y   | Y   | Y   |   | Y  |  
   |  | Y  |  |  
   
   |   |  |  
   
  |  
   
  |  |  | | | | | | | |
   |  |  |  |  |  |  | 1  |  | Y  |  
   |  |  |   | Y   | Y   | Y   |
| 11           | 3   |   
   
   
  | 1  |   |   |   |   |   |   | Ŷ   |   |   |  |  
   | 1  |  |  |  
   
   |   |  |  
   
  |  
   
  |  |  | | | | | | | |
   |  |  |  |  |  |  |  |  |  |  
   |  |  |   |   | -   |   |
| 11           |   | Υ   
   
   
  | 1  |   |   |   | Y   |   |   |   | Y   |   | Y  | Y  
   | Y  |  | Y  | ΥY   
   
   |   |  |  
   
  | Y  
   
  |  |  | | | | | | | |
   |  | -  |  | Y  | Y  | Y  |  |  |  |  
   |  | Y  | -   |   | Y   | Y   |
| 15 3         | 1   |   
   
   
  |  |   |   |   |   |   |   | Y   |   |   |  |  
   |  |  |  |  
   
   |   |  |  
   
  |  
   
  |  |  | | | | | | | |
   |  |  |  |  |  |  |  |  |  |  
   |  |  |   | Y   | -   |   |
|              | 2 Y   |   
   
   
  | Y  | Y   | Y   | -   | Y   | -   |   |   | Y   |   | Y  | Y  
   | Y  |  | -  | Y  
   
   | -   | Y  |  
   
  | Y  
   
  | -  | γ γ  | Y  
   | -  | -  |  |  |  |  |  | -  |  |  
   |  | -  | Y   | -   |   | Y   |
|              | 44         12           55         10           77         6           13         10           77         6           13         6           14         20           15         13           14         12           14         10           14         10           15         13           16         10           17         10           18         2           13         2           13         3           14         5           15         5           15         5           15         5           15         5           16         5           17         10           18         5           15         5           13         8           10         5           13         8           10         5 | 44         12         3         Y           12         3         10         4         Y           13         10         4         Y         Y           14         20         4         Y           13         6         4         Y           13         6         4         Y           13         6         4         Y           14         12         3         Y           14         12         3         Y           14         10         2         Y           13         4         3         4         Y           13         2         4         Y         Y           13         4         3         2         4           13         2         3         4         3           13         2         3         3         2         3           13         2         3         3         4         3         4           13         2         3         3         3         4         3           14         2         2         7         7         2         7 </th <th><math display="block">\begin{array}{c c c c c c c c c c c c c c c c c c c </math></th> <th><math display="block"> \begin{array}{c c c c c c c c c c c c c c c c c c c </math></th> <th><math display="block"> \begin{array}{c c c c c c c c c c c c c c c c c c c </math></th> <th><math display="block"> \begin{array}{c c c c c c c c c c c c c c c c c c c </math></th> <th><math display="block"> \begin{array}{c c c c c c c c c c c c c c c c c c c </math></th> <th><math display="block"> \begin{array}{c c c c c c c c c c c c c c c c c c c </math></th> <th>14         12         3         Y</th> <th>14         12         3         Y</th> <th>14         12         3         Y</th> <th>14         12         3         Y</th> <th>14     12     3     Y&lt;</th> <th>14     12     3     Y&lt;</th> <th>14     12     3     Y&lt;</th> <th>14     12     3     Y&lt;</th> <th>14     12     3     Y    
Y     Y&lt;</th> <th>4     12     3     Y<!--</th--><th>14       12       3       Y</th><th>4       12       3       Y</th><th>4     12     3     Y<!--</th--><th>4     12     3     Y<!--</th--><th>4       12       3       Y</th><th>4       12       3       Y</th><th>4       12       3       Y</th><th>4         12         3         Y</th><th>4       12       3       Y</th><th>4       12       3       Y       Y       Y       Y       Y       Y       Y   
   Y       Y</th><th>4       12       3       Y</th><th>4       12       3       Y       <thy< th=""> <thy< th=""> <thy< th="">    &lt;</thy<></thy<></thy<></th><th>4       12       3       Y</th><th>4       12       3       Y</th><th>4       12       3       Y</th><th>4       12       3       Y</th><th>4       12       3       Y       V</th><th>4       12       3       Y</th><th>4       12       3       Y</th><th>1         1      
  1         1</th><th>1         1         3         Y</th><th>1         1         3         Y         V</th><th>1         1         3         7</th></th></th></th> | $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | $ \begin{array}{c c c c c c c c c c c c c c c c c c c $ | $ \begin{array}{c c c c c c c c c c c c c c c c c c c $ | $ \begin{array}{c c c c c c c c c c c c c c c c c c c $ | $ \begin{array}{c c c c c c c c c c c c c c c c c c c $ | $ \begin{array}{c c c c c c c c c c c c c c c c c c c $ | 14         12         3         Y | 14         12         3         Y | 14         12         3         Y | 14         12         3         Y | 14     12     3     Y< | 14     12     3     Y  
  Y     Y     Y     Y     Y     Y     Y     Y     Y     Y< | 14     12     3     Y< | 14     12     3     Y< | 14     12     3     Y< | 4     12     3     Y </th <th>14       12       3       Y</th> <th>4       12       3       Y</th> <th>4     12     3     Y<!--</th--><th>4     12     3     Y<!--</th--><th>4       12       3       Y</th><th>4       12       3       Y</th><th>4       12       3       Y</th><th>4         12         3         Y 
       Y         Y</th><th>4       12       3       Y</th><th>4       12       3       Y</th><th>4       12       3       Y</th><th>4       12       3       Y       <thy< th=""> <thy< th=""> <thy< th="">    &lt;</thy<></thy<></thy<></th><th>4       12       3       Y</th><th>4       12       3       Y</th><th>4       12       3       Y</th><th>4       12       3       Y</th><th>4       12       3       Y       V</th><th>4       12       3       Y   
   Y       Y</th><th>4       12       3       Y</th><th>1         1</th><th>1         1         3         Y</th><th>1         1         3         Y         V</th><th>1         1         3         7</th></th></th> | 14       12       3       Y | 4       12       3       Y | 4     12     3     Y </th <th>4     12     3     Y<!--</th--><th>4       12       3       Y
      Y       Y</th><th>4       12       3       Y</th><th>4       12       3       Y</th><th>4         12         3         Y</th><th>4       12       3       Y</th><th>4       12       3       Y</th><th>4       12       3       Y</th><th>4       12       3       Y       <thy< th=""> <thy< th=""> <thy< th="">    &lt;</thy<></thy<></thy<></th><th>4       12       3       Y</th><th>4       12       3       Y</th><th>4       12       3       Y</th><th>4       12       3       Y       Y       Y       Y       Y       Y       Y       Y       Y       Y 
     Y       Y</th><th>4       12       3       Y       V</th><th>4       12       3       Y</th><th>4       12       3       Y</th><th>1         1</th><th>1         1         3         Y</th><th>1         1         3         Y         V</th><th>1         1         3         7</th></th> | 4     12     3     Y </th <th>4       12       3       Y</th> <th>4       12       3       Y      
Y       Y</th> <th>4       12       3       Y</th> <th>4         12         3         Y</th> <th>4       12       3       Y</th> <th>4       12       3       Y</th> <th>4       12       3       Y</th> <th>4       12       3       Y       <thy< th=""> <thy< th=""> <thy< th="">    &lt;</thy<></thy<></thy<></th> <th>4       12       3       Y</th> <th>4       12       3       Y</th> <th>4       12       3       Y</th> <th>4       12       3       Y
      Y       Y</th> <th>4       12       3       Y       V</th> <th>4       12       3       Y</th> <th>4       12       3       Y</th> <th>1         1</th> <th>1         1         3         Y</th> <th>1         1         3         Y         V</th> <th>1         1         3         7</th> | 4       12       3       Y | 4       12       3       Y | 4       12       3       Y    
  Y       Y | 4         12         3         Y | 4       12       3       Y | 4       12       3       Y | 4       12       3       Y | 4       12       3       Y <thy< th=""> <thy< th=""> <thy< th="">    &lt;</thy<></thy<></thy<> | 4       12       3       Y | 4       12       3       Y | 4       12       3       Y | 4       12       3       Y | 4       12       3       Y       V  
    V       V       V       V       V       V       V       V       V       V       V       V       V       V | 4       12       3       Y | 4       12       3       Y | 1         1 | 1         1         3         Y | 1         1         3         Y         V | 1         1         3         7 |

This is just to give you an impression of the work. I identified 43 symptoms that patients complain about. The last 5 columns are related to their diagnosis. You can see how many mentioned a biopsy.

	patient	suspects	credits	genetics	haves	care provider	occupation	activities	drugs	supplements	diets	therapies	exercise	progres
3	AW	does not know;	Prednisone;		Osteoporosis;	dermatologist;	Nurse	does not say;	PDN;	NSAIDs; Tramadol;		Physiotherapy;		l;
			Physiotherapy;		Diabetes;		Practitioner		MTX;	Gabapentin;		Myofascial	walking;	
			Myofascial		Hyperlipidemia; Gastric		(NP);			Amitriptyline;		release;		
			release;		reflux; Anemia;					Doxepin; Lyrica;				
			stretching;		Vitamin D deficiency;					Tylenol;				
					Lymphedema;					Doxycycline;				
					Hyper/hypo					Fosamax;				
					thyroidism;					Omeprazole;				
4	LT	physical exertion;	Prednisone;		Localized	rheumatologist;	Registered	does not say;	PDN;	Reclast infusions	Avoid wheat;		exercises;	l; S; I;
		insect bite;	Methotrexate;		scleroderma/morphea;		Nurse (RN);		HCQ;	(for osteoporosis);	Avoid white sugar;		walking;	
		stress;	stretching;		Gastric reflux;				MTX;	Fosamax; Calcium;	Eat more organic		yoga;	
			exercise; sleep;		Conjunctival chemosis;					Vitamin B; Vitamin	foods; Eat more			
										D3; Omeprazole;	vegetables and			
										CoQ-10; Biotin; Fish				
										oil; Folic acid;	proteins: Avoid			
											processed foods:			
16	МК	insect bite;	Prednisone;	CIDP (father);	Hashimoto's	dermatologist;	Registered	does not say;	IVP; PDN;	Ciprofloxacin;	Avoid gluten;	Occupational	exercises;	I; R;
			Methotrexate:		thyroiditis; Lyme		Nurse (RN);		MTX;	Doxycycline;	Drink lots of	therapy for	stretching:	
			hand exercises;		disease; Allergy to				· ·	Cetaphil cream;	water;	hands;	,	
					wheat; Chronic cough;					Multi-Vitamin; Folic	-	Physiotherapy;		
										acid; Calcium;		/*******		
										Vitamin D3:				
										Magnesium;				
21	EJ	Campylobacter;	Prednisolone:	Spondylitis	Cerebrovascular	rheumatologist;	HR director	public house	PDL;	Antihistamine;	Drink lots of	Myofascial	walking:	I; S; R
		overworked;	Methotrexate;	(maternal	Accident (CVA);		for hotel	manager at	MTX;	Omeprazole;	water; Eat more	release	running;	., =,,
		stress;	Azathioprine;	cousin);	/ lecident (etrij)		group;	night;	AZA: IVP:	Calcium; Vitamin	vegetables and	(Bowen);	, anne,	
		50,055,	Myofascial				Broup,		,,,	D3;	fruit; Avoid	Lymphatic		
			release;							55,		drainage;		
			release,								Avoid sugar; Avoid			
											dairy;	nyurutnerapy,		
	JR	physical exertion;	adequate	Ulcerative	Allergies;	teaching	college	running;	IVP; PDL;			Physiotherapy;	stretching	1;
24		insect bite;	hydration;	colitis	Gastroenteritis:	hospital;	lecturer;	weight	MTX;			ingsiotiterupy,	physical	.,
24		insect bite,	stretching;	(father);	oustroenternis,	nospital,	icedurer,	training;	HCQ;				training:	
24								crannig,	AZA;				crannig,	


Everything else a patient says is grouped under 13 subjects to complete the patient record. The genetics column is for anything the patient has in their family. The haves column is for other conditions the patient has. I am interested in thyroid issues simply because my mother's mother had Graves' disease. She died during the thyroidectomy operation. My mother had systemic lupus. My father didn't know what she had until a few weeks before she died, they didn't tell him even though he was a doctor. That was in 1954. You would think that much has changed since then, that doctors would include patients earlier in their deliberations. But from what the forum patients are saying and my own experience, this is not happening as much as it should. During the weeks leading up to my diagnosis there were times when I felt like a bystander instead of the owner of my disease.




I wanted to see how the forum patients compared with the clinical studies. The next few slides show where they agree and where they differ.

study		year	females	males	total	ages	average
University of Pittsburgh, Per	nnsylvania	1979	11	9	20	20-68	44
Mayo Clinic, Rochester, Min	nesota	1988	29	23	52	11-72	47
Stadtspital Triemli Zürich, U	niversitätsspital Bas	sel 2006	6	5	11	1-72	50
Hôpital Pitié-Salpêtrière, Pa	ris	2011	20	14	34		53
Mayo Clinic, Jacksonville, Flo	orida	2014	8	8	16	30-75	52
Brigham & Women's, Bosto	n, Massachusetts	2015	43	20	63		57
Patient survey of online for	ıms	2017	156	86	242	2-73	40
studies	patients	females	mal	es	ages		average
Clinical studies	196	60%	409	%	1-75		52
Patient survey	242	64%	369	%	2-73		40


After summarizing the clinical studies in one line we can see that forum patients appear on average to be younger than the studies have suggested. It is also interesting that the gender balance almost matches the clinical studies, this was unexpected as I had heard that females far outnumber males in online health forums.



In age ranges, the forum data agree with the studies in that younger EF patients are mostly female. The peak of women in their 50s is a departure from the studies. It might be a forum effect. I just don't know. You can see that the pattern for males is quite regular.




The less frequent drugs were usually prescribed only after the main ones had failed, but not always for that reason. Other health conditions sometimes limited the choices. I have kept the list of drugs to only those which were prescribed for Eosinophilic Fasciitis, not for other conditions the patients might have had.



The next slide tries to correlate progress with treatments.


mproved							CEL	AZA	CYC	MED	IVG	IFX	CIM	ALB	LDN	DEP	LFL	KEN	IMC	CPH	RTX	diets	therapies	exercises
	39%	94	88	61	22	11	6	10		2	2	3	2		3		1				1	20	42	38
Remission	28%	68	58	37	15	8	11	5	3	2	3	2	2	3			1		1	1		22	30	26
Relapsed	17%	40	37	25	13	4	4	5	5	2	1	1	1			3		2				2	9	5
Unknown	17%	40	30	21	2	1	2	1					1									3	5	4
ALL	100%	242	213	144	52	24	23	21	8	6	6	6	6	3	3	3	2	2	1	1	1	47	86	73
					1											- / • /		204	4)					
				L	ast k	nov	vn s	tate	cor	rela	ted	with	tre	atm	ent	s (IV	ayo	201	.4)					
progress	percent	patients	PDN	мтх	HCQ	IVP	CEL	AZA	СУС	MED	IVG	IFX	СІМ	ALB	LDN	DEP	LFL	KEN	IMC	СРН	RTX	diets	therapies	exercises
mproved	44%	7	6	7				1																
Remission	19%	3	3	3	1																			
Relapsed	38%	6	6	6	2			1																
ALL	100%	16	15	16	3			2																
ITX=Meth CQ=Hydro 'P=Intrave EL=CellCej ZA=Azathi YC=Cyclos IED=Medr	otrexate oxychlorod nous met ot (mycop oprine (Ir porine rol (oral m	ednisolone quine (Pla chylpredni ohenolate nuran) nethylprec nunoglob cade)	quenil isolone mofet Inisolo	) e (Solu il) one)		ol)		LDN DEP LFL= KEN IMC CPH RTX: diet	=Low =Injec =Leflur =Kena =Iverr =Cyclo =Ritux s=glut	ndazole Dose M ted me nomide alog (tr nectin ophosp cimab ( en-free =physic	Valtrex ethylp e (Arav iamcir vhamic Rituxa e, vega	rednis va) nolone de (Cy nn) an, ave	e aceto toxan) oid su	onide) ) gar an	d salt,	etc.								

It shows that the patients whose state is improved, or in remission, were more proactive. This is an important finding that has come out of the patient stories. The Mayo 2014 study is shown just for comparison. Like most of the studies, it seems only interested in the drugs. I found some anomalies in their report which I have sent to them for comment.




		Datients n	rogress histor	y (Forums 201	7)	]
	71	improved		y (10101113 201	. / )	
	46	improved	remission			
	23	improved	relapsed			-
	20	improved	relapsed	improved		-
	20	improved	relapsed	remission		
	11	improved	remission	relapsed		
	6	relapsed				
	3	improved	remission	relapsed	improved	
	2	improved	remission	relapsed	remission	
	40	unknown				
						1
		Patients p	progress histo	ry (Mayo 2014	1)	
	7	improved				
	4	improved	relapsed			
	3	remission				
	2	improved	remission	relapsed		1
						1
7-06-22 15:02			Martin O. G. FitzGeral	ld © 2017		


In the forums about one third relapsed at some point. A few patients go into a remission-relapse-remission cycle that lasts for years. Some say they can control it with diet and exercise. The Mayo 2014 study said that 70% of patients relapsed at some point, but it enthusiastically added that they "responded well to re-treatment with MTX". While the 2016 Brigham and Women's study made a similar finding, their report was more cautious and concluded with, quote, "Further investigation is needed to determine an appropriate treatment algorithm for patients with EF.".




New patients ask how long (in weeks or months) until they will be "cured". The reality is less optimistic, these are years, but it does show that most of us recover sooner or later. There are a few not shown whose history went longer than 7 years. Some went 20 years or more.




But this shows it is taking too long to diagnose this disease. Some patients lost time by delaying their first doctor visit. Quite a few complained that their doctor did not listen to them. Others were given medication on a speculative basis without a proper diagnosis. The best doctors, like my generalist, enlisted the help of others until the disorder could be identified. A very few patients were lucky enough to have a doctor who was fairly sure they knew what they had straight away, because they had already seen this disorder and recognized the symptoms.




What helped patients the most?




Back in 1988 the Mayo Clinic study found that about an equal number of EF patients recovered either on prednisone alone, or on hydroxychloroquine alone. In the forums very few patients were given one drug alone. Most received several so it was hard for them to know what worked best. Exercise, physical therapies and diet are given more credit by patients than by the clinical studies.




No one seems to know what causes or triggers this disease but some patients have their ideas.




Stress is most often suspected by patients. Especially if we add physical "trauma" such as wounds or operations, not included here. If there was unusual physical exertion they often qualify it by remarks such as, "I have been doing this exercise for years so why should it cause a problem now?" But the stress factor is blamed without any qualifiers. Forum patients are saying it quite loudly so I think they should be heard.





Among the 242 patients there were nearly 300 other health conditions. Some, such as Aplastic Anemia, took precedence over their EF and reduced their treatment options. "Other" goes off the screen as there are nearly 300 more. So I picked just the top ones.



Last month a woman posted that her husband, who has Eosinophilic Fasciitis, had had a related disorder, Eosinophilic Esophagitis, some years previously. Now, his son has that disorder too. This does seem very suggestive, two eosinophilic disorders in the father, one in the son.

	Eosinophilic Fasciitis in Families	
	(1) Eosinophilic Fasciitis in a pair of siblings (1989) http://onlinelibrary.wiley.com/doi/10.1002/anr.1780320117/pdf	
	(2) Eosinophilic Fasciitis in a father and son (1994) http://ard.bmj.com/content/annrheumdis/53/4/281.1.full.pdf	
	(3) Familial eosinophilic fasciitis and breast cancer (1994) https://academic.oup.com/rheumatology/article-abstract/33/1/93/1777698/familial-eosinophilic-fasciitis-and- breast-cancer?redirectedFrom=fulltext	
	(4) Eosinophilic Fasciitis in twin sisters (2013) http://www.experienceproject.com/stories/Have-Eosinophilic-Fasciitis/2995461	
	(5) Eosinophilic Fasciitis in Siblings (2013)	
	(6) Familial eosinophilic fascitis induced by toxic oil (1988) https://www.ncbi.nlm.nih.gov/pubmed/3287053	
2017-06-22 15:02	Martin O. G. FitzGerald © 2017	36

These looked to me like cases that could not be blamed on environmental factors or coincidence. I think this argues for further study into the genetic side of this disorder. The next slides look at how the W-H-O classifies eosinophilic disorders.

## World Health Organization International Classification of Diseases

2012 Workshop report from the National Institutes of Health Taskforce on the Research Needs of Eosinophil-Associated Diseases (TREAD)

Baltimore and Bethesda, Md, Atlanta, Ga, Madison, Wis, Rochester, Minn, Aurora, Colo, Salt Lake City, Utah, Scottsdale, Ariz, Winnipeg, Manitoba, Canada, Cincinnati, Ohio, Richmond, Va, <mark>Bern, Switzerland</mark>, and Boston, Mass

"many eosinophilic disorders are lumped together with other disorders [which] precludes determination of the true prevalence of specific eosinophil-associated diseases"

2017-06-22 15:02


Martin O. G. FitzGerald © 2017

37


I chanced upon this report. It can be summarized in that sentence taken from it, that "many eosinophilic disorders are lumped together with **other disorders** [which] precludes determination of the true prevalence of **specific** eosinophil-associated diseases". So bad news for us patients.

Eosinophil-associated disease	ICD-9 CM currently available (named disorders)	Eosinophil-disease appropriate?*
Chronic eosinophilic leukemia (CEL)	205.1 (CMyeloidL) 207.8 (CEL-NOS) 238.71 ('Other' leukemia)	No
Churg-Strauss syndrome	447.6 (Vasculitis, not otherwise specified)	No
Eosinophilic cystitis	595.9 (Cystitis, unspecified)	No
Eosinophilic colitis	558.42	Yes
Eosinophilic esophagitis	530.13	Yes
Eosinophilic fasciitis	729.4 (Fasciitis, unspecified)	No
Eosinophilic folliculitis	704.8 (Other unspecified diseases of the follicle)	No
Eosinophilic gastritis	535.7	Yes
Eosinophilic gastritis and colitis	558.4	Yes
Eosinophilic pneumonia	518.3 (Pulmonary eosinophilia)	No
Hypereosinophilic syndrome (HES)	288.3 (Eosinophilia)	No
Nasal polyposis	471.8	Yes

This table in that report shows that Eosinophilic Fasciitis is among the orphaned conditions assigned a "No" for not being appropriately classified. That was in ICD Revision 9.



In ICD Revision 10 the disease has its own classification with a new number. According to the workshop report, quote, this should "make it easier for medical professionals and researchers". It sounds like an opportunity for **health software** as well.



Just a few remarks to conclude. In a local newspaper, La Gruyère, a doctor recently warned readers that the internet was only a source of information, not a diagnostic tool. I diagnosed my whooping cough 10 years ago by listening to online recordings of coughs. My doctor was impressed as he had mis-diagnosed it as asthma.

Patients will try to self-diagnose online, so rather than resist this, health professionals could collaborate with software developers so we all benefit.

Machine learning is improving by the day, but it needs access to far more health data than what seems to be on offer at present. This will lead to earlier diagnoses and better treatments.

If you have patient data on a local computer somewhere, at the very least an offline backup will protect it from being encrypted by ransom software.

My generalist, when I told him about this talk, warned me that "most doctors are not very interested in what patients have to say". I hope there are not too many of those in this audience.

Thank you for your time.